SM
KNSA icon

SG3 Management’s Kiniksa Pharmaceuticals KNSA Stock Holding History

SG3 Management’s Portfolio KNSA Stock Details KNSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-8,500
Closed -$118K – 1127
2021
Q2 		$118K Sell
8,500
-11,000
-56% -$167K ﹤0.01% 882
2021
Q1 		$361K Buy
+19,500
New +$399K 0.01% 853

Other funds holding KNSA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $36.8B AUM 42.13% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return

SG3 Management's KNSA Position: Q3 2021 in Review

SG3 Management sold out of Kiniksa Pharmaceuticals (KNSA) in Q3 2021, closing a stake of 8,500 shares — an estimated $118K sold.

SG3 Management first reported a position in KNSA in Q1 2021 and held it in 2 quarters. The position peaked at $361K in Q1 2021. 101 funds tracked by Wall St. Rank hold KNSA as of Q3 2021.

  • SG3 Management reported no remaining Kiniksa Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • SG3 Management sold 8,500 Kiniksa Pharmaceuticals shares in Q3 2021, an estimated $118K.
  • SG3 Management first reported a position in Kiniksa Pharmaceuticals in Q1 2021 and held it in 2 quarters.
  • SG3 Management's Kiniksa Pharmaceuticals position peaked at $361K in Q1 2021.
  • 101 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q3 2021.

Based on SG3 Management's 13F filing for Q3 2021, filed 15 Nov 2021.